SynAct Pharma Appoints Anders Dyhr Toft, MD, Ph.D., as Chief Medical Officer
SynAct Pharma AB (“SynAct”) today announced the appointment of Anders Dyhr Toft, MD, PhD, as Chief Medical Officer (CMO), effective August 1, 2021. He will head up clinical development and medical affairs in close collaboration with SynAct’s CSO Dr. Thomas Jonassen. Dr. Toft brings critical experience to the SynAct team as the company advances its lead selective melanocortin asset AP1189 through clinical development.Dr. Toft joins SynAct following almost two decades at Novo Nordisk where he in senior leadership roles in both Medical Affairs, Operations and Commercial has played key roles in